Drug-Induced Prolongation of the QT Interval

New England Journal of Medicine

Volumn 350, Issue 10, 2004, Pages 1013-1022

  Roden, Dan M ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ASTEMIZOLE; BEPRIDIL; CALCIUM CHANNEL BLOCKING AGENT; CHLORPROMAZINE; CISAPRIDE; CLARITHROMYCIN; DISOPYRAMIDE; DOFETILIDE; DOMPERIDONE; DROPERIDOL; ERYTHROMYCIN; GREPAFLOXACIN; HALOFANTRINE; HALOPERIDOL; IBUTILIDE; LEVACETYLMETHADOL; LIDOFLAZINE; MESORIDAZINE; METHADONE; PENTAMIDINE; PROCAINAMIDE; QUINIDINE; SERTINDOLE; SOTALOL; SPARFLOXACIN; TERFENADINE; TERODILINE; THIORIDAZINE; UNINDEXED DRUG;

DECISION MAKING; ELECTROCARDIOGRAPHY; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; REVIEW; RISK FACTOR; SUDDEN DEATH; SYNCOPE; TORSADE DES POINTES;

ACTION POTENTIALS; ELECTROCARDIOGRAPHY; HUMANS; LONG QT SYNDROME; PHARMACEUTICAL PREPARATIONS; RISK FACTORS; SYNCOPE; TORSADES DE POINTES;

EID: 1442306232     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMra032426     Document Type: Review

References (79)

1. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002;287:2215-20.
2. Haverkamp W, Breithardt G, Camm AJ, et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications: report on a policy conference of the European Society of Cardiology. Eur Heart J 2000;21:1216-31.
3. Anderson ME, Al Khatib SM, Roden DM, Califf RM. Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management. Am Heart J 2002;144: 769-81.
4. Selzer A, Wray HW. Quinidine syncope, paroxysmal ventricular fibrillations occurring during treatment of chronic atrial arrhythmias. Circulation 1964;30:17-26.
5. Dessertenne F. La tachycardie ventriculaire à deux foyers opposés variables. Arch Mal Coeur 1966;59:263-72.
6. Jervell A, Lange-Nielsen F. Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval, and sudden death. Am Heart J 1957;54:59-68.
7. Romano C, Gemme G, Pongiglione R. Aritmie cardiache rare in dell'eta pediatrica. Clin Pediatr 1963;45:656-83.
8. Ward OC. A new familial cardiac syndrome in children. J Ir Med Assoc 1964;54: 103-6.
9. Viskin S, Fish R, Zeltser D, et al. Arrhythmias in the congenital long QT syndrome: how often is torsade de pointes pause dependent? Heart 2000;83: 661-6.
10. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993;270:2590-7.
11. Kay GN, Plumb VJ, Arciniegas JG, Henthorn RW, Waldo AL. Torsades de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients. J Am Coll Cardiol 1983;2:806-17.
12. Roden DM, Woosley RL, Primm RK. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J 1986; 111:1088-93.
13. Choy AMJ, Darbar D, Dell'Orto S, Roden DM. Exaggerated QT prolongation and cardioversion of atrial fibrillation. J Am Coll Cardiol 1999;34:396-401.
14. Nowinski K, Gadler F, Jensen-Urstad M, Bergfeldt L. Transient proarrhythmic state following atrioventricular junction radiofrequency ablation: pathophysiologic mechanisms and recommendations for management. Am J Med 2002;113:596-602.
15. Torp-Pedersen C, Møller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and leftventricular dysfunction. N Engl J Med 1999;341: 857-65.
16. Houltz B, Darpo B, Edvardsson N, et al. Electrocardiographic and clinical predictors of torsades de pointes induced by almokalant infusion in patients with chronic atrial fibrillation or flutter: a prospective study. Pacing Clin Electrophysiol 1998;21:1044-57.
17. Carlsson L, Abrahamsson C, Andersson B, Duker G, Schiller-Linhardt G. Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisations. Cardiovasc Res 1993;27:2186-93.
18. Donger C, Denjoy I, Berthet M, et al. KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome. Circulation 1997;96:2778-81.
19. Napolitano C, Schwartz PJ, Brown AM, et al. Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. J Cardiovasc Electrophysiol 2000;11:691-6.
20. Sesti F, Abbott GW, Wei J, et al. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci U S A 2000;97:10613-8.
21. Ks potassium channels. Circulation 1999;100:Suppl I:I-495. abstract.
22. Splawski I, Timothy KW, Tateyama M, et al. Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia. Science 2002;297:1333-6.
23. Kr: implications for torsades de pointes and reverse use-dependence. Circulation 1996;93:407-11.
24. Locati EH, Zareba W, Moss AJ, et al. Age- and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: findings from the International LQTS Registry. Circulation 1998; 97:2237-44.
25. Wu Y, Anderson ME. Reduced repolarization reserve in ventricular myocytes from female mice. Cardiovasc Res 2002;53:763-9.
26. Pham TV, Sosunov EA, Gainullin RZ, Danilo P Jr, Rosen MR, Impact of sex and gonadal steroids on prolongation of ventricular repolarization and arrhythmias induced by I(K)-blocking drugs. Circulation 2001; 103:2207-12.
27. Pham TV, Sosunov EA, Anyukhovsky EP, Danilo P Jr, Rosen MR. Testosterone diminishes the proarrhythmic effects of dofetilide in normal female rabbits. Circulation 2002; 106:2132-6.
28. Drici MD, Burklow TR, Haridasse V, Glazer KI, Wossley RL. Sex hormones prolong the QT interval and downregulate potassium channel expression in the rabbit heart. Circulation 1996;94:1471-4.
29. Roden DM. Taking the "idio" out of "idiosyncratic": predicting torsades de pointes. Pacing Clin Electrophysiol 1998;21:1029-34.
30. Gbadebo TD, Trimble RW, Khoo MS, Temple J, Roden DM, Anderson ME. Calmodulin inhibitor W-7 unmasks a novel electrocardiographic parameter that predicts initiation of torsade de pointes. Circulation 2002;105:770-4.
31. Shimizu W, Antzelevitch C. Differential effects of beta-adrenergic agonists and antagonists in LQT1, LQT2 and LQT3 models of the long QT syndrome. J Am Coll Cardiol 2000;35:778-86.
32. Stambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield LK, VanderLugt JT. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation 1996; 94:1613-21.
33. Velebit V, Podrid P, Lown B, Cohen BH, Graboys TB. Aggravation and provocation of ventricular arrhythmias by antiarrhythmic drugs. Circulation 1982;65:886-94.
34. Pratt CM, Ruberg S, Morganroth J, et al. Dose-response relation between terfenadine (Seldane) and the QTc interval on the scalar electrocardiogram: distinguishing a drug effect from spontaneous variability. Am Heart J 1996;131:472-80.
35. Khongphatthanayothin A, Lane J, Thomas D, Yen L, Chang D, Bubolz B. Effects of cisapride on QT interval in children. J Pediatr 1998;133:51-6.
36. Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003;349:474-85.
37. Woosley RL, Chen Y, Freiman JP, Gillis RA. Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993;269:1532-6.
38. Hennessy S, Bilker WB, Knauss JS, et al. Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. BMJ 2002; 325:1070.
39. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med 2003;348:1866-74.
40. Vila JA, Gang Y, Rodriguez Presedo JM, Fernandez-Delgado M, Barro S, Malik M. A new approach for TU complex characterization. IEEE Trans Biomed Eng 2000;47: 764-72.
41. Malik M, Farbom P, Batchvarov V, Hnatkova K, Camm AJ. Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval. Heart 2002;87: 220-8.
42. Roden DM, Hoffman BF. Action potential prolongation and induction of abnormal automaticity by low quinidine concentrations in canine Purkinje fibers: relationship to potassium and cycle length. Circ Res 1985;56:857-67.
43. Brachmann J, Scherlag BJ, Rosenshtraukh LV, Lazzara R, Bradycardia-dependent triggered activity: relevance to drug-induced multiform ventricular tachycardia. Circulation 1983;68:846-56.
44. Yan GX, Shimizu W, Antzelevitch C. Characteristics and distribution of M cells in arterially perfused canine left ventricular wedge preparations. Circulation 1998;98: 1921-7.
45. Akar FG, Yan GX, Antzelevitch C, Rosenbaum DS. Unique topographical distribution of M cells underlies reentrant mechanism of torsade de pointes in the long-QT syndrome. Circulation 2002;105: 1247-53.
46. Sicouri S, Antzelevitch C. Drug-induced afterdepolarizations and triggered activity occur in a discrete subpopulation of ventricular muscle cells (M cells) in the canine heart: quinidine and digitalis. J Cardiovasc Electrophysiol 1993;4:48-58.
47. el-Sherif N, Caref EB, Yin H, Restivo M. The electrophysiological mechanism of ventricular arrhythmias in the long QT syndrome: tridimensional mapping of activation and recovery patterns. Circ Res 1996; 79:474-92.
48. El-Sherif N, Caref EB, Chinushi M, Restivo M. Mechanism of arrhythmogenicity of the short-long cardiac sequence that precedes ventricular tachyarrhythmias in the long QT syndrome. J Am Coll Cardiol 1999; 33:1415-23.
49. Burashnikov A, Antzelevitch C. Block of I(Ks) does not induce early afterdepolarization activity but promotes beta-adrenergic agonist-induced delayed afterdepolarization activity. J Cardiovasc Electrophysiol 2000; 11:458-65.
50. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995;80:795-803.
51. Wang Q, Shen J, Splawski I, et al. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell 1995;80:805-11.
52. Wang Q, Curran ME, Splawski I, et al. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. NatGenet 1996;12:17-23.
53. Ks function. Nat Genet 1997;17:338-40.
54. Keating MT, Sanguinetti MC. Molecular and cellular mechanisms of cardiac arrhythmias. Cell 2001;104:569-80.
55. Mohler PJ, Schott JJ, Gramolini AO, et al. Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature 2003;421:634-9.
56. Kr potassium channel, Cell 1995;81:299-307.
57. Priori SG, Napolitano C, Schwartz PJ. Low penetrance in the long-QT syndrome: clinical impact. Circulation 1999;99:529-33.
58. Yang P, Kanki H, Drolet B, et al. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation 2002;105:1943-8.
59. Zhang S, Zhou Z, Gong Q, Makielski JC, January CT. Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. Circ Res 1999; 84:989-98.,
60. Yang T, Snyders D, Roden DM. Drug block of I(kr): model systems and relevance to human arrhythmias. J Cardiovasc Pharmacol 2001;38:737-44.
61. Nattel S, Quantz MA. Pharmacological response of quinidine induced early afterdepolarisations in canine cardiac Purkinje fibres: insights into underlying ionic mechanisms. Cardiovasc Res 1988;22:808-17.
62. Lazzara R. Amiodarone and torsades de pointes. Ann Intern Med 1989;111:549-51.
63. Gintant GA, Limberis JT, McDermott JS, Wegner CD, Cox BF. The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis. J Cardiovasc Pharmacol 2001;37:607-18.
64. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR Jr. Torsades de pointes occurring in association with terfenadine use. JAMA 1990;264:2788-90.
65. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR, Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA 1993;269:1513-8. [Erratum, JAMA 1993;269:2088.]
66. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR, Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA 1993;269:1513-8. [Erratum, JAMA 1993;269:2088.]
67. Davies AJ, Harindra V, McEwan A, Ghose RR. Cardiotoxic effect with convulsions in terfenadine overdose. BMJ 1989;298:325.
68. Venturini E, Borghi E, Maurini V, Vecce R, Carnicelli A. Allungamento dell'intervallo Q-T ed aritmie ventricolari ipercinetiche probabilmente indotte dall'uso di terfenadine in paziente con cirrosi epatica. Recenti Prog Med 1992;83:21-2.
69. Kamisako T, Adachi Y, Nakagawa H, Yamamoto T. Torsades de pointes associated with terfenadine in a case of liver cirrhosis and hepatocellular carcinoma. Intern Med 1995;34:92-5.
70. Ohnishi K, Yoshida H, Shigeno K, et al. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann Intern Med 2001;133:881-5.
71. Huan SY, Yang CH, Chen YC. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: a useful salvage therapy. Leuk Lymphoma 2000;38:283-93.
72. Singh BN. Comparative efficacy and safety of bepridil and diltiazem in chronic stable angina pectoris refractory to diltiazem. Am J Cardiol 1991;68:306-12.
73. Department of Health and Human Services, Public Health Service, Food and Drug Administration, Center for Drug Evaluation and Research. Anti-Infective Drugs Advisory Committee, 67th meeting, Thursday, October 21, 1999 (transcript). (Accessed February 9, 2004, at http://www.fda.gov/ohrms/dockets/ac/99/transcpt/3558t2a.pdf.)
74. Food and Drug Administration, Center for Drug Evaluation and Research. Psychopharmacologic Drugs Advisory Committee proceedings, Wednesday, July 19, 2000 (transcript). (Accessed February 9, 2004, at http://www.fda.gov/ohrms/dockets/ac/OO/transcripts/3619tla.pdf.)
75. Abernethy DR, Flockhart DA. Molecular basis of cardiovascular drug metabolism: implications for predicting clinically important drug interactions. Circulation 2000; 101:1749-53.
76. Burkhart GA, Sevka MJ, Temple R, Honig PK. Temporal decline in filling prescriptions for terfenadine closely in time with those for either ketoconazole or erythromycin. Clin Pharmacol Ther 1997;61:93-6.
77. Cavuto NJ, Woosley RL, Sale M. Pharmacies and prevention of potentially fatal drug interactions. JAMA 1996;275:1086-7.
78. Woosley RL. Drug labeling revisions - guaranteed to fail? JAMA 2000;284:3047-9.
79. Temple RJ, Himmel MH. Safety of newly approved drugs: implications for prescribing. JAMA 2002;287:2273-5.